Neoantigen × AI
Daily research signal
TRACKING / TRIAL TRACKER

NCT07329894 — Beijing GoBroad Hospital neoantigen vaccine trial

Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer

TrackingPhase 1RecruitingRegistry updated 12 Feb 2026
Phase 1phaseRecruitingregistry status18enrollment2027-08primary completion

Registry IDNCT07329894
Lead sponsorBeijing GoBroad Hospital
CollaboratorsNeoCura
PhasePhase 1
StatusRecruiting
IndicationGastrointestinal Cancer
Enrollment18 participants (target)
Start date2026-02
Primary completion2027-08 (est.)
Last registry update12 Feb 2026

Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07329894), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.

No modality, tumor or player hub covers this study yet. Browse the field map for the axes the daily brief does track.

What phase is NCT07329894?

NCT07329894 (Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer) is registered on ClinicalTrials.gov as Phase 1, sponsored by Beijing GoBroad Hospital.

Is NCT07329894 recruiting?

As of the 2026-02-12 registry update, NCT07329894 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.

Who is running NCT07329894?

The lead sponsor is Beijing GoBroad Hospital. Collaborators: NeoCura.

What condition does NCT07329894 study?

The registered condition is Gastrointestinal Cancer. Primary completion is listed as 2027-08 (estimated).

Are results available for NCT07329894?

neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07329894.

Back to the full neoantigen vaccine trial tracker 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.